Breaking AI & Tech News Analyzed

Prosecutors in Florida have moved to subpoena Tiger Woods' prescription drug records from a pharmacy, following his recent vehicle crash and DUI arrest. The legendary golfer's records from Lewis Pharmacy in Palm Beach, Florida, are being sought for the period from the start of the year through last month.The subpoena aims to obtain comprehensive details on Woods' prescription medication, including:the times prescriptions were filledthe number of pills dispenseddosage amountsany instructions provided with the medication, such as warnings about drivingAccording to court documents, prosecutors in Martin County, Florida, are seeking this information to aid in their investigation. Any objections to the subpoena must be filed within 10 days. Woods has pleaded not guilty in his DUI case.Woods' vehicle crashed on a beachside road on Jupiter Island, where he was traveling at high speeds in a 30-mile per hour zone. The accident resulted in $5,000 in damage to the truck. Although a Breathalyzer test showed no signs of alcohol, Woods refused a urine test.Following the incident, Woods announced he would be stepping away to seek treatment. This is not his first leave of absence following a car crash; in 2009, he took a four-month break after a previous accident.

What would Henrik Ibsen’s iconic heroine Nora look like in today’s Britain? In this bold re‑imagining, playwright Anya Reiss transports the 19th‑century drama into a world of high‑salary banking, social‑media façades and post‑pandemic consumer excess. Set against a sleek, white‑goods‑strewn stage designed by Hyemi Shin, the story follows Nora (played by Romola Garai) as the wife of a lucrative London banker, Torvald (Tom Mothersdale), who is also battling drug addiction. Though presented as a “trophy wife”, Nora is far sharper than her husband realises – she has secretly rescued the family from financial collapse and funded Torvald’s recovery, all while maintaining a veneer of festive, pre‑Christmas splurging. The familiar Ibsen plot points survive the update: a blackmail threat from Torvald’s colleague Nils Krogstad (James Corrigan) and a visit from the destitute, marriage‑for‑money‑failed friend Kristine (Thalissa Teixeira). Their interactions expose the tension between outward affluence and hidden desperation. Reiss’s version is unmistakably contemporary, peppering dialogue with references to Instagram, a stock market rattled by conflict in the Middle East, and the relentless pursuit of material status. This backdrop reframes the marital power struggle as a clash of class and modern capitalism, asking whether love can ever be insulated from market forces. Despite the heavy thematic load, the cast delivers a series of compelling performances. Garai’s Nora oscillates between calculated seduction – even donning a provocative nurse’s outfit for a flirtatious dance – and a keen intellect that refuses to be reduced to a mere commodity. Her portrayal suggests that, for Nora, the body has become a form of currency, yet she remains acutely aware of the performative nature of both marriage and motherhood. Notably, the children appear only through baby‑monitor audio, a deliberate choice that underscores the couple’s emotional distance and mirrors the original’s focus on Nora’s internal emancipation. The climax arrives in a charged confrontation where Nora questions, “Is love meant to be subject to the market?” The line encapsulates Reiss’s preoccupation with the commodification of intimacy, even as it feels like a summarising refrain rather than a fresh revelation. Ultimately, the production offers a nuanced, if occasionally over‑engineered, vision of Ibsen’s feminist aspirations. It hints at a future where Nora and Torvald might seek couples therapy to untangle their financial and emotional entanglements – a decidedly modern resolution. A Doll’s House runs at the Almeida Theatre, London, until 23 May.

Ecuador has escalated tensions with Colombia by recalling its ambassador, Arturo Felix Wong, from Bogota. This move comes in response to criticisms from Colombian President Gustavo Petro regarding the case of former Ecuadorian Vice President Jorge Glas, who is currently serving a lengthy prison sentence for corruption.Glas, a left-wing figure, has been at the center of a high-profile criminal case that has stirred tensions across Latin America. He was arrested in a controversial police raid on the Mexican embassy in Quito two years ago, where he had sought asylum. The raid was authorized by the right-wing government of Ecuadorian President Daniel Noboa, who has denounced criticisms of the Glas case as a violation of his country's sovereignty.President Petro has referred to Glas as a 'political prisoner' and has called for his transfer to Colombian custody after granting him citizenship last September. Petro has also raised concerns about Glas's health and wellbeing, stating that he is suffering from severe malnutrition and muscle mass loss due to his imprisonment.The diplomatic row between Ecuador and Colombia is part of a long-running spat between the two leaders. Since March, Noboa has imposed 50-percent tariffs on Colombian imports, accusing Colombia of being too lax in its fight against drug trafficking. Petro, in turn, has accused Noboa of carrying out a bombing campaign near the Colombian border, resulting in the recovery of 27 charred bodies.Ecuador's Foreign Minister, Gabriela Sommerfeld, confirmed the recall of the ambassador, stating that the criticisms of the Glas case were 'uncalled for and a provocation'. The move is seen as a further escalation of tensions between the two countries, which have been experiencing strained relations since the Mexican embassy raid in 2024.

Researchers have made a significant breakthrough in understanding why weight-loss medications, such as GLP1 receptor agonists, work better for some individuals than others. A recent study published in Nature has identified genetic variations in two genes involved in gut hormone pathways that regulate appetite and digestion. These genetic variations may help account for different weight-loss results or side-effects when taking glucagon-like peptide 1 (GLP1) medicines, which mimic natural gut hormones to regulate appetite, insulin release, and digestion. The study analyzed data from 27,885 patients on GLP1 drugs and found that specific genetic variants were associated with slightly more weight loss or side-effects like nausea and vomiting. The findings suggest that genetic differences may contribute to why people respond differently to weight-loss jabs. However, the overall impact of genetics appeared to be modest, with non-genetic factors such as sex, drug type, dose, and duration appearing to explain a substantially larger proportion of variability. The study's results reinforce that while there is substantial variability in response to GLP1 therapies, genetics is only one part of a much more complex picture. According to Marie Spreckley, an obesity expert at the University of Cambridge, the study provides plausible evidence that genetic variants could affect outcomes. However, she notes that the magnitude of these genetic effects is small in clinical terms, and that behavioral, clinical, and treatment-related factors remain the dominant drivers of outcomes. The study's authors suggest that their findings could support future efforts to use genetic information when making treatment choices for obesity. However, Spreckley cautions that the evidence is not yet sufficient to support using genetic information to guide treatment decisions in routine clinical practice.

Joe Eszterhas, the swaggering pitchman of 80s and 90s Hollywood, has lived a life of excess and creativity. He wrote hits like Jagged Edge and co-scripted Flashdance, earning a then-record $3m for his Basic Instinct screenplay.Eszterhas's life story is a harrowing, rollicking immigrant's tale that whisks its hero from his birth in war-torn Hungary through the refugee camps of Allied-occupied Austria to the US rust belt. He covered the Kent State massacre as a cub reporter and interviewed Charles Manson in prison.Now 81, Eszterhas is plotting a Hollywood comeback with a rebooted Basic Instinct. He received a reported $2m from Amazon MGM studios for his script and stands to make a further $2m if and when it is filmed. The new story juggles copycat serial killers with elements of the supernatural.Eszterhas has always relished a good public scrap, and his reboot is described as anti-woke. This has sparked concerns that he may be co-opted and become a political football. However, Eszterhas insists that he is not afraid of controversy and sexuality.Despite his past struggles with drinking and drugs, Eszterhas has been clean and sober for decades. He has written a 750-page memoir, Hollywood Animal, and told his Tinseltown war stories on a recent multi-part media podcast, Ugly, Irresponsible, & Childish.

Judith Rapoport, a leading child psychiatrist, passed away at 92, leaving a legacy defined by her groundbreaking work on obsessive‑compulsive disorder (OCD). Her 1989 book, The Boy Who Couldn’t Stop Washing, translated into more than twenty languages, presented complex research in a clear, jargon‑free style that resonated with a broad audience. OCD is characterized by compulsive rituals—re‑tying shoelaces, repeatedly checking switches, or incessant hand‑washing—that can dominate a person’s daily life. Before Rapoport’s book, many sufferers concealed their symptoms out of shame, unaware that they were not alone. Rapoport’s research demonstrated that OCD has a neurological foundation and may affect up to 2% of the population, challenging prevailing beliefs that it stemmed from overly strict parenting. She proved that the disorder can be hereditary and responsive to medication. In a pivotal 1989 double‑blind trial, she showed that the antidepressant clomipramine significantly reduced OCD symptoms, prompting the U.S. Food and Drug Administration to approve its use for the condition—a landmark moment in psychiatric treatment. Patients and colleagues credit her work with reducing stigma. "Reading Rapoport’s book washed away my shame," recalled Charles Gentz, who lives with OCD, while Professor Gabrielle Shapiro of the Icahn School of Medicine noted that the book “reduced the stigma for these people.” Rapoport herself reflected, “If my work alleviated just part of their pain, then it was not wasted time.” Born in New York City to a schoolteacher mother and a businessman father, she grew up with a literary lineage—her grandfather translated Ibsen into Yiddish. She excelled academically, graduating magna cum laude from Swarthmore College in 1955** and earning her medical degree from Harvard Medical School in 1959, where she met her husband, Stanley Rapoport. After early positions at Mount Sinai and the Massachusetts Mental Health Center, she and her husband secured fellowships in Sweden, conducting research at Uppsala University and the Karolinska Institute on women seeking abortions abroad. Returning to the United States, Rapoport joined the National Institute of Mental Health (NIMH) in 1976. There she led the institute’s child psychiatry branch from 1984, steering American psychiatry away from Freudian models toward a **biology‑focused** approach. Beyond OCD, she made significant contributions to the understanding of attention‑deficit hyperactivity disorder (ADHD) and childhood schizophrenia. Her 1978 study revealed that amphetamine improved concentration in both hyperactive and control children, contradicting the notion that stimulants only calm hyperactivity. Using MRI, she showed that childhood schizophrenia is progressive, involving loss of brain matter—a finding that shifted the focus from parenting to neurobiology. Rapoport’s expertise reached mainstream audiences through appearances on shows hosted by Oprah Winfrey and Larry King, further amplifying her message. By the time she retired in 2017, she had authored over 300 scientific papers, several books, and earned prestigious honors, including fellowship in the Institute of Medicine (1991) and the American Academy of Arts and Sciences (2000). Colleague Gabrielle Shapiro described her as “a pioneer who turned child psychiatry into a modern, evidence‑based discipline.” Outside the laboratory, she enjoyed music, theatre, hiking, and gardening. She is survived by her husband, two sons, and four grandsons.

Scientists have made a groundbreaking discovery, identifying a distinct 'neural fingerprint' produced by psychedelic drugs in the human brain when users experience their mind-altering effects.This breakthrough finding emerged from a comprehensive study that combined 11 brain imaging datasets from around the world, involving over 500 brain scans from 267 people in five countries. The research focused on five psychedelic substances: LSD, psilocybin, DMT, mescaline, and ayahuasca.The study revealed that these substances have a shared impact on the brain's behavior, dissolving the usual hierarchy of brain systems and flattening the hierarchy, which may underlie the raw access to one's own consciousness that some people describe during psychedelic experiences.Dr. Danilo Bzdok, a senior author on the study from McGill University in Montreal, Canada, explained that all five drugs change brain function in common ways, despite some differences in how they alter brain activity. The most striking effect was stronger communication between brain networks that engage in higher-level thinking and more primitive networks linked to vision and sensation.The research, published in Nature Medicine, provides a solid foundation for psychedelic research, which is crucial if these drugs are to become widespread therapies for mental health conditions such as depression, schizophrenia, and post-traumatic stress disorder.Dr. Emmanuel Stamatakis, a senior co-author on the study from the University of Cambridge, emphasized the importance of large-scale, coordinated evidence in the field of psychedelic research, which is moving quickly and needs to mature responsibly.

The peptide-testing industry has seen a significant surge in demand, with laboratories testing thousands of unregulated substances claiming to support weight-loss and wellness. This growth is largely driven by the injectable peptide craze, with experts warning about the lack of reliable safety data and quality control.Peptides are short chains of amino acids, which can be found naturally in the body or made synthetically in laboratories. They include active ingredients in prescription weight-loss drugs, such as Wegovy, as well as experimental compounds pushed online by the booming biohacking and anti-ageing industries.Laboratories, such as Finnrick in Texas, have reported a substantial increase in testing requests, with around 60,000 samples processed annually, including roughly 2,000 orders from the UK since 2024. About a third of the products analysed failed basic quality checks, with issues including incorrect identity, purity, and quantity.Experts, including Dr. Luke Turnock and Peter Magic, have highlighted the risks associated with these unregulated substances, including potential long-term harms such as increased cancer risk and damage to organs. The large profit margins have also drawn nefarious actors into the supply chain.The UK is a significant market for peptides, with 2,000 testing orders since 2024, tied with Canada for third place globally. The Royal Pharmaceutical Society's Prof Amira Guirguis emphasized the need for oversight, traceability, and quality assurance in the peptide market.

Donald Trump has repeatedly framed inflation as a "hoax" and declared that he has "won affordability," yet independent analyses reveal that his touted initiatives deliver only marginal relief for most Americans.One of his most publicized programs, the TrumpRX prescription‑drug platform, lists just 61 medications out of the thousands needed nationwide. Moreover, price comparisons show that a medium dose of Wegovy costs $349 on TrumpRX, while the same dose sells for $163 in Japan and $198 in Germany. Similar gaps appear for diabetes drug Xigduo and autoimmune medication Xeljanz, which are significantly cheaper abroad.The website markets itself as a solution for uninsured, cash‑paying patients, but it does nothing for the roughly 85 % of Americans who already have prescription coverage.On housing, Trump’s executive order banning Wall Street firms from buying single‑family homes is unlikely to move the needle. Institutional investors own only about 2 % of such homes, while the nation faces a shortage of roughly 4.7 million units, according to Zillow. The ongoing war in Iran has also pushed mortgage rates higher, further straining affordability.Gasoline prices have surged since the Iran conflict began, climbing to an average of $4.10 per gallon – a 37 % increase from the pre‑war level of $2.98.Food costs tell a similar story. The Consumer Price Index shows a 3.1 % rise in overall food prices from February 2025 to February 2026, with coffee up 18.4 %, beef up 14.4 %, and fresh vegetables up 5.4 %. Tariffs championed by the administration have contributed to these hikes.International bodies echo domestic concerns. The OECD projects U.S. inflation to exceed 4 % this year, largely driven by the Iran war, a level higher than the 3 % rate recorded at the end of the Biden administration.Trump also claims to have eliminated taxes on overtime and Social Security benefits. In reality, overtime earnings are still subject to federal income tax on the base wage and to full Social Security and Medicare payroll taxes. Only the overtime premium enjoys a partial tax break. Likewise, more than half of Social Security recipients will continue to owe income tax on their benefits, contradicting the administration’s “no‑tax” narrative.Other initiatives, such as the “Trump Accounts” child‑savings program, provide a one‑time $1,000 seed deposit and allow families to contribute up to $5,000 annually. While beneficial for affluent households, the scheme offers limited assistance to families living paycheck‑to‑paycheck.Policy decisions have also raised costs for vulnerable groups. By opposing extensions of Obamacare subsidies, average health‑care premiums have risen by over 20 % for more than 20 million people. Simultaneously, proposed cuts to LIHEAP threaten heating and cooling assistance for roughly 6 million low‑income households.In sum, Trump’s affordability rhetoric serves more as political branding than substantive economic relief. The modest scope of his programs and the persistence of rising prices suggest that most working‑class Americans will see little improvement in their day‑to‑day expenses.